US 12337033
Encapsulated glycolipid antigens for treatment of neoplastic diseases
granted A61KA61K2039/5154A61K2039/55572
Quick answer
US patent 12337033 (Encapsulated glycolipid antigens for treatment of neoplastic diseases) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- EnGeneIC Molecular Delivery Pty Ltd
- Grant date
- Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/5154, A61K2039/55572, A61K2039/55594, A61K2039/585